Display options
Cite
de Candia P, Prattichizzo F, Garavelli S, et al. Effect of time and titer in convalescent plasma therapy for COVID-19. iScience. 2021;24(8):102898doi: 10.1016/j.isci.2021.102898.
de Candia, P., Prattichizzo, F., Garavelli, S., La Grotta, R., De Rosa, A., Pontarelli, A., Parrella, R., Ceriello, A., & Matarese, G. (2021). Effect of time and titer in convalescent plasma therapy for COVID-19. iScience, 24(8), 102898. https://doi.org/10.1016/j.isci.2021.102898
de Candia, Paola, et al. "Effect of time and titer in convalescent plasma therapy for COVID-19." iScience vol. 24,8 (2021): 102898. doi: https://doi.org/10.1016/j.isci.2021.102898
de Candia P, Prattichizzo F, Garavelli S, La Grotta R, De Rosa A, Pontarelli A, Parrella R, Ceriello A, Matarese G. Effect of time and titer in convalescent plasma therapy for COVID-19. iScience. 2021 Aug 20;24(8):102898. doi: 10.1016/j.isci.2021.102898. Epub 2021 Jul 22. PMID: 34316549; PMCID: PMC8297982.
Copy Download .nbib Format: NLM
Share it on

iScience. 2021 Aug 20;24(8):102898. doi: 10.1016/j.isci.2021.102898. Epub 2021 Jul 22.

Effect of time and titer in convalescent plasma therapy for COVID-19.

iScience

Paola de Candia, Francesco Prattichizzo, Silvia Garavelli, Rosalba La Grotta, Annunziata De Rosa, Agostina Pontarelli, Roberto Parrella, Antonio Ceriello, Giuseppe Matarese

Affiliations

  1. IRCCS MultiMedica, 20138 Milano, Italy.
  2. Istituto per l'Endocrinologia e l'Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), 80131 Naples, Italy.
  3. Dipartimento di Malattie Infettive ed Emergenze Infettive, Divisione di Malattie Infettive Respiratorie, Ospedale Cotugno, AORN dei Colli, 80131 Naples, Italy.
  4. Treg Cell Lab, Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80131 Naples, Italy.

PMID: 34316549 PMCID: PMC8297982 DOI: 10.1016/j.isci.2021.102898

Abstract

The clinical benefit of convalescent plasma (CP) for patients with coronavirus disease (COVID)-19 is still debated. In this systematic review and meta-analysis, we selected 10 randomized clinical trials (RCTs) and 15 non-randomized studies (total number of patients = 22,591) of CP treatment and evaluated two different scenarios: (1) disease stage of plasma recipients and (2) donated plasma antibody titer, considering all-cause mortality at the latest follow-up. Our results show that, when provided at early stages of the disease, CP significantly reduced mortality: risk ratio (RR) 0.72 (0.68, 0.77), p < 0.00001, while provided in severe or critical conditions, it did not (RR: 0.94 [0.86, 1.04], p = 0.22). On the other hand, the benefit on mortality was not increased by using plasma with a high-antibody titer compared with unselected plasma. This meta-analysis might promote CP usage in patients with early-stage COVID-19 in further RCTs to maximize its benefit in decreasing mortality, especially in less affluent countries.

© 2021 The Authors.

Keywords: systems medicine; virology

Conflict of interest statement

F.P. reports personal fees from Berlin-Chemie/Menarini, outside the submitted work. A.C. reports personal fees from Bayer, Ely Lilly, Novo Nordisk, Theras, and Berlin Chemie; grants and personal fees

References

  1. Nature. 2020 Mar;579(7798):270-273 - PubMed
  2. Nat Med. 2021 Apr;27(4):622-625 - PubMed
  3. J Clin Invest. 2021 Feb 1;131(3): - PubMed
  4. JAMA Oncol. 2021 Jun 17;: - PubMed
  5. Infect Dis Ther. 2020 Sep;9(3):525-536 - PubMed
  6. Nature. 2021 May;593(7857):130-135 - PubMed
  7. N Engl J Med. 2021 Jan 21;384(3):289-291 - PubMed
  8. N Engl J Med. 2021 Feb 25;384(8):693-704 - PubMed
  9. Lancet. 2020 Feb 22;395(10224):565-574 - PubMed
  10. Blood. 2020 Aug 6;136(6):755-759 - PubMed
  11. Int J Infect Dis. 2020 Dec;101:194-200 - PubMed
  12. PLoS Med. 2021 Mar 3;18(3):e1003415 - PubMed
  13. Nat Med. 2020 Nov;26(11):1708-1713 - PubMed
  14. Infez Med. 2020 Sep 1;28(3):357-366 - PubMed
  15. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6 - PubMed
  16. Nature. 2021 May;593(7857):142-146 - PubMed
  17. Intern Emerg Med. 2021 Apr 10;: - PubMed
  18. N Engl J Med. 2020 Feb 20;382(8):727-733 - PubMed
  19. JCI Insight. 2021 Feb 22;6(4): - PubMed
  20. Cancer Med. 2020 Nov;9(22):8571-8578 - PubMed
  21. Lancet. 2020 Mar 28;395(10229):1054-1062 - PubMed
  22. Euro Surveill. 2020 Nov;25(45): - PubMed
  23. Rev Invest Clin. 2020;72(3):159-164 - PubMed
  24. Medicina (B Aires). 2020;80(5):417-424 - PubMed
  25. Blood. 2020 Aug 6;136(6):652-654 - PubMed
  26. J Infect Dis. 2015 Jan 1;211(1):80-90 - PubMed
  27. J Crit Care. 2020 Dec;60:328-333 - PubMed
  28. Clin Microbiol Rev. 2020 Aug 12;33(4): - PubMed
  29. Transfus Apher Sci. 2020 Dec;59(6):102922 - PubMed
  30. N Engl J Med. 2021 Mar 18;384(11):1015-1027 - PubMed
  31. Blood. 2020 Aug 6;136(6):759-762 - PubMed
  32. Haematologica. 2020 Jul 23;105(12):2834-2840 - PubMed
  33. JCI Insight. 2021 Mar 22;6(6): - PubMed
  34. J Infect Dis. 2020 Nov 13;222(12):1974-1984 - PubMed
  35. Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100763 - PubMed
  36. Eur J Haematol. 2021 Jul;107(1):24-28 - PubMed
  37. J Clin Invest. 2020 Dec 1;130(12):6728-6738 - PubMed
  38. Medicina (B Aires). 2020;80 Suppl 6:9-17 - PubMed
  39. Transfus Apher Sci. 2020 Oct;59(5):102875 - PubMed
  40. Cell Mol Immunol. 2021 Apr;18(4):936-944 - PubMed
  41. Cochrane Database Syst Rev. 2020 Jul 10;7:CD013600 - PubMed
  42. JCI Insight. 2020 Jun 18;5(12): - PubMed
  43. J Intern Med. 2021 Apr;289(4):559-573 - PubMed
  44. Microorganisms. 2020 Nov 28;8(12): - PubMed
  45. Cell Host Microbe. 2021 May 12;29(5):747-751.e4 - PubMed
  46. Lancet Microbe. 2021 Jan;2(1):e13-e22 - PubMed
  47. Transfus Apher Sci. 2021 Feb;60(1):103017 - PubMed
  48. Cytokine Growth Factor Rev. 2020 Jun;53:33-37 - PubMed
  49. Lancet Infect Dis. 2020 Apr;20(4):398-400 - PubMed
  50. Commun Biol. 2021 Jan 29;4(1):129 - PubMed
  51. Int J Infect Dis. 2021 Feb;103:439-446 - PubMed
  52. Transfusion. 2021 Jul;61(7):2099-2106 - PubMed
  53. Cell. 2021 Apr 15;184(8):2201-2211.e7 - PubMed
  54. Transfus Apher Sci. 2020 Oct;59(5):102847 - PubMed
  55. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496 - PubMed
  56. Commun Biol. 2021 Feb 24;4(1):267 - PubMed
  57. J Clin Invest. 2020 Nov 2;130(11):6141-6150 - PubMed
  58. Lancet. 2020 Feb 15;395(10223):497-506 - PubMed
  59. PLoS One. 2021 Jan 7;16(1):e0244853 - PubMed
  60. Br J Haematol. 2021 Feb;192(4):706-713 - PubMed
  61. BMJ. 2020 Oct 22;371:m3939 - PubMed
  62. JAMA. 2020 Aug 4;324(5):460-470 - PubMed
  63. J Infect Dis. 2020 Oct 13;222(10):1620-1628 - PubMed
  64. Int J Infect Dis. 2021 Jan;102:332-334 - PubMed
  65. Blood Cells Mol Dis. 2021 May;88:102548 - PubMed
  66. J Med Virol. 2021 Feb;93(2):1111-1118 - PubMed
  67. Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):12528 - PubMed
  68. Sci Rep. 2021 May 11;11(1):9927 - PubMed
  69. N Engl J Med. 2021 Feb 18;384(7):619-629 - PubMed
  70. J Med Virol. 2021 Mar;93(3):1678-1686 - PubMed
  71. Am J Pathol. 2020 Nov;190(11):2290-2303 - PubMed
  72. Transfusion. 2021 Mar;61(3):692-698 - PubMed
  73. J Clin Invest. 2021 Apr 1;131(7): - PubMed
  74. N Engl J Med. 2021 Feb 18;384(7):610-618 - PubMed
  75. Eur J Pharmacol. 2020 Dec 15;889:173644 - PubMed
  76. Turk J Haematol. 2021 Jan 25;38(1):15-21 - PubMed

Publication Types